Evidence map›Paper›PMID 42247401›Full record

ArticlePloS one2026

Pre-analytical variables affecting breast cancer biomarker expression: A controlled single-specimen study of fixation duration, cold ischemia time, and fixative preparation in a low-resource setting.

Clément Parfait Ndengue, Paul Jean Adrien Atangana, Gilbert Roger Ateba, Samuel Honoré Mandengue, Emile Telesphore Mboudou, Carole Else Eboumbou Moukoko

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Clément Parfait NdengueDouala Gynaeco-Obstetric and Pediatric Hospital (DGOPEH), Douala, Cameroon.ORCID https://orcid.org/0000-0003-1267-7409
Paul Jean Adrien AtanganaDouala Gynaeco-Obstetric and Pediatric Hospital (DGOPEH), Douala, Cameroon.
Gilbert Roger AtebaDouala Gynaeco-Obstetric and Pediatric Hospital (DGOPEH), Douala, Cameroon.
Samuel Honoré MandengueFaculty of Sciences, University of Douala, Douala, Cameroon.
Emile Telesphore MboudouDouala Gynaeco-Obstetric and Pediatric Hospital (DGOPEH), Douala, Cameroon.
Carole Else Eboumbou MoukokoFaculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOptimal pre-analytical management of breast tissue specimens, particularly formalin fixation, is essential for accurate immunohistochemical (IHC) biomarker assessment in invasive breast cancer. Although international guidelines suggest using 4% neutral buffered formalin with controlled fixation time, many laboratories in low-resource settings deviate from these standards. This study aimed to determine whether three pre-analytical variables - fixation duration, cold ischemia time, and fixative preparation (4% neutral buffered versus 4% non-buffered formaldehyde) - impact the preservation and evaluation of tissue biomarkers in invasive breast cancer.

methodsWe conducted an exploratory, proof-of-concept, experimental study using fresh mastectomy tissue from a 34-year-old patient with invasive ductal carcinoma (pT4, hormone receptor-positive, HER2-negative, Ki67 = 40%) who had not received neoadjuvant chemotherapy. Fifty microsamples (5-15 mm in length, approximately 1 mm in diameter) were obtained using a 14-gauge core needle biopsy device and divided into four cohorts: (1) 19 samples fixed in 4% neutral buffered formaldehyde for 0.5 to 144 hours; (2) 19 samples fixed in 4% non-buffered formaldehyde for 0.5 to 144 hours; (3) 6 samples with delayed fixation (0.5 to 8 hours) then fixed in neutral buffered formaldehyde for 10 hours; (4) 6 samples with delayed fixation (0.5 to 8 hours) then fixed in non-buffered formaldehyde for 10 hours. Hormone receptors (estrogen receptor-ER, progesterone receptor-PR) and Ki67 expression were evaluated by IHC using the Allred scoring system and current international recommendations.

resultsFixative preparation had a statistically significant, yet small, impact on biomarker evaluation. The mean percentage of ER-positive cells was 96.89 ± 0.74% with neutral buffered formaldehyde compared to 94.32 ± 1.51% with non-buffered formaldehyde (p = 0.011). Similar trends were seen for PR (94.89 ± 0.95% vs. 92.63 ± 1.67%, p = 0.027) and staining intensity. However, Allred scores remained unchanged. Fixation duration was significantly correlated with biomarker expression (Spearman ρ between -0.60 and -0.83, p ≤ 0.007), with stable values from 0.5 to 48 h and a significant decline beyond 72 h (one-way ANOVA across fixation windows: all p < 0.01). Cold ischemia time was strongly correlated with decreased biomarker expression regardless of fixative preparation. Hormone receptor expression and Ki67 remained stable with minimal Allred score changes for up to 2 hours of cold ischemia, but significantly decreased after 2 hours, with scores decreasing in proportion to the duration of ischemia (p < 0.05).

conclusionsIn this single-specimen controlled experiment, non-buffered formaldehyde preserved tissue biomarkers with small but measurable differences relative to neutral buffered formaldehyde for IHC analysis, although these findings require validation in multi-patient studies. Consistent with current guidelines, a cold ischemia time of up to 1 hour maintained adequate biomarker preservation. These preliminary results may be relevant for pathology laboratories in resource-limited settings where neutral buffered formalin may not be easily accessible, and warrant further investigation across diverse tumor types and baseline expression levels, particularly tumors with ER-low-positive (1-10%) or heterogeneous expression.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFixativesTissue FixationAdultCold IschemiaFemaleFormaldehydeHumansImmunohistochemistryKi-67 AntigenReceptors, ProgesteroneResource-Limited SettingsTime FactorsBiomarkers, TumorFixativesFormaldehydeKi-67 AntigenReceptors, Progesterone

Identifiers

PMID42247401
PMCPMC13240924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.